KALA PHARMACEUTICALS INC's ticker is KALA and the CUSIP is 483119103. A total of 126 filers reported holding KALA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.35 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $799,000 | -0.5% | 118,493 | 0.0% | 0.01% | -9.1% |
| Q4 2020 | $803,000 | -10.4% | 118,493 | -0.8% | 0.01% | -21.4% |
| Q3 2020 | $896,000 | -21.9% | 119,441 | +9.5% | 0.01% | -17.6% |
| Q2 2020 | $1,147,000 | -47.7% | 109,107 | -56.3% | 0.02% | -61.4% |
| Q1 2020 | $2,193,000 | +36.0% | 249,445 | -42.9% | 0.04% | +109.5% |
| Q4 2019 | $1,613,000 | +6.0% | 437,220 | +9.3% | 0.02% | -4.5% |
| Q3 2019 | $1,522,000 | -31.8% | 399,936 | +14.3% | 0.02% | -24.1% |
| Q2 2019 | $2,233,000 | +71.5% | 349,936 | +122.2% | 0.03% | +70.6% |
| Q1 2019 | $1,302,000 | +69.5% | 157,474 | +0.3% | 0.02% | +54.5% |
| Q4 2018 | $768,000 | -62.7% | 157,000 | +4.7% | 0.01% | -38.9% |
| Q2 2018 | $2,059,000 | -10.4% | 149,953 | +3.3% | 0.02% | -5.3% |
| Q1 2018 | $2,298,000 | -34.6% | 145,158 | -23.6% | 0.02% | -32.1% |
| Q4 2017 | $3,513,000 | +20.8% | 190,000 | +49.3% | 0.03% | +27.3% |
| Q3 2017 | $2,907,000 | – | 127,274 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON CORP | 1,142,360 | $7,745,000 | 4.83% |
| RA Capital Management | 10,874,613 | $73,730,000 | 1.03% |
| Mesirow Financial Investment Management, Inc. | 43,431 | $294,462,000 | 0.93% |
| Parkman Healthcare Partners LLC | 272,445 | $1,847,000 | 0.47% |
| Samsara BioCapital, LLC | 601,162 | $4,076,000 | 0.41% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 102,198 | $693,000 | 0.40% |
| Eventide Asset Management | 3,450,000 | $23,391,000 | 0.36% |
| Orbimed Advisors | 5,465,030 | $37,053,000 | 0.32% |
| Vivo Capital, LLC | 786,883 | $5,335,000 | 0.24% |
| Knights of Columbus Asset Advisors LLC | 169,429 | $1,149,000 | 0.12% |